Gout and the risk of Parkinson's disease: A cohort study

Arthritis Care and Research

Volumn 59, Issue 11, 2008, Pages 1549-1554

  De Vera, Mary ^a   Rahman, M Mushfiqur ^b   Rankin, James ^b   Kopec, Jacek ^a   Gao, Xiang ^c   Choi, Hyon ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ARTHRITIS RESEARCH CENTRE OF CANADA   (Canada)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGOUT AGENT; DIURETIC AGENT; FUROSEMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; THIAZIDE DIURETIC AGENT;

AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GOUT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORBIDITY; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SEX;

AGED; AGED, 80 AND OVER; ANTIOXIDANTS; BRITISH COLUMBIA; CASE-CONTROL STUDIES; COHORT STUDIES; DIURETICS; FEMALE; FOLLOW-UP STUDIES; GOUT; HUMANS; INCIDENCE; MALE; MULTIVARIATE ANALYSIS; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; URIC ACID;

EID: 56049092243     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.24193     Document Type: Article

References (44)

1. Choi H, Mount D, Reginato A, for the American College of Physicians and the American Physiological Society. Pathogenesis of gout. Ann Intern Med 2005;143:499-516.
2. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 2005;118:816-26.
3. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981;78:6858-62.
4. Church WH, Ward VL. Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation [published erratum appears in Brain Res Bull 1994;34:423]. Brain Res Bull 1994;33:419-25.
5. Tohgi H, Abe T, Takahashi S, Kikuchi T. The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson's disease. J Neural Transm Park Dis Dement Sect 1993;6:119-26.
6. Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am J Epidemiol 1996;144:480-4.
7. De Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 2005;58:797-800.
8. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 2007;166:561-7.
9. Larumbe Ilundain R, Ferrer Valls JV, Vines Rueda JJ, Guerrero D, Fraile P. Case-control study of markers of oxidative stress and metabolism of blood iron in Parkinson's disease. Rev Esp Salud Publica 2001;75:43-53. In Spanish.
10. Annanmaki T, Muuronen A, Murros K. Low plasma uric acid level in Parkinson's disease. Mov Disord 2007;22:1133-7.
11. Alonso A, Rodriguez LA, Logroscino G, Hernan MA. Gout and risk of Parkinson disease: a prospective study. Neurology 2007;69:1696-700.
12. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52:916-23.
13. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
14. Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007;56:1021-8.
15. University of British Columbia Centre for Health Services and Policy Research. The BC Linked Health Database. 1996. URL: http://www.chspr.ubc.ca/ data.
16. Harrold LR, Saag KG, Yood RA, Mikuls TR, Andrade SE, Fouayzi H, et al. Validity of gout diagnoses in administrative data. Arthritis Rheum 2007;57:103-8.
17. Singh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis Rheum 2007;57:822-9.
18. Meier CR, Jick H. Omeprazole, other antiulcer drugs and newly diagnosed gout. Br J Clin Pharmacol 1997;44:175-8.
19. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005;64:267-72.
20. Charlson M, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
21. Deyo R, Cherkin D, Ciol M. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.
22. Hernan M, Logroscino G, Garcia Rodriguez L. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 2006;66:1097-9.
23. Gambassi G, Landi F, Peng L, Brostrup-Jensen C, Calore K, Hiris J, et al, on behalf of the SAGE Study Group. Validity of diagnostic and drug data in standardized nursing home resident assessments: potential for geriatric pharmacoepidemiology. Med Care 1998;36:167-79.
24. De Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525-35.
25. De Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 2004;63:1240-4.
26. Baldereschi M, Di Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E, et al, for the ILSA Working Group. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. Neurology 2000;55:1358-63.
27. Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984;16:278-82.
28. Chen RC, Chang SF, Su CL, Chen TH, Yen MF, Wu HM, et al. Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan County, Taiwan. Neurology 2001;57:1679-86.
29. Morens DM, Davis JW, Grandinetti A, Ross GW, Popper JS, White LR. Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men. Neurology 1996;46:1044-50.
30. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157:1015-22.
31. Schwarzschild M, Schwid S, Marek K, Oakes D, Watts A, Lang A, et al. Serum urate level predicts progression of Parkinson's disease. Proceedings of the 36th Annual Meeting of the Society for Neuroscience; 2006 Oct 14-18; Atlanta, Georgia. Washington, DC: Society for Neuroscience; 2006.
32. Ascherio A, LeWitt P, Watts A. CSF as well as serum urate are predictors of Parkinson's disease progression. Proceedings of the 10th International Conference of Parkinson's Disease and Movement Disorders; 2006 Oct 28 to Nov 2; Kyoto, Japan. Hoboken (NJ): Wiley Interscience; 2006.
33. Rundles RW, Wyngaarden JB. Drugs and uric acid. Annu Rev Pharmacol 1969;9:345-62.
34. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002;80:101-10.
35. Yu ZF, Bruce-Keller AJ, Goodman Y, Mattson MP. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res 1998;53:613-25.
36. Everse J, Coates PW. The cytotoxic activity of lactoperoxidase: enhancement and inhibition by neuroactive compounds. Free Radic Biol Med 2004;37:839-49.
37. Anderson RF, Harris TA. Dopamine and uric acid act as antioxidants in the repair of DNA radicals: implications in Parkinson's disease. Free Radic Res 2003;37:1131-6.
38. Jones DC, Gunasekar PG, Borowitz JL, Isom GE. Dopamine-induced apoptosis is mediated by oxidative stress and is enhanced by cyanide in differentiated PC12 cells. J Neurochem 2000;74:2296-304.
39. Hooper DC, Bagasra O, Marini JC, Zborek A, Ohnishi ST, Kean R, et al. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci U S A 1997;94:2528-33.
40. Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004;31:1575-81.
41. Sarawate C, Brewer K, Yang W, Patel P, Schumacher HR Jr, Saag K, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925-34.
42. Hernan MA, Logroscino G, Rodriguez LA. A prospective study of alcoholism and the risk of Parkinson's disease. J Neurol 2004;251 Suppl 7:vII14 -7.
43. Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease [review]. Arthritis Rheum 2004;50:2400-14.
44. Hernan M, Takkouche, B, Caamano-Isorna, F, Gestal-Otero J. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002;52:276-84.